Page 251 - 2021_05-Haematologica-web

Letters to the Editor
8. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412(6844):341-346.
9. Ennishi D, Jiang A, Boyle M, et al. Double-hit gene expression sig- nature defines a distinct subgroup of germinal center B-cell-like diffuse large B-Cell lymphoma. J Clin Oncol. 2019;37(3):190-201.
10. Juskevicius D, Lorber T, Gsponer J, et al. Distinct genetic evolu- tion patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequenc- ing analysis. Leukemia. 2016;30(12):2385-2395.
11. Greenawalt DM, Liang WS, Saif S, et al. Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum. Oncotarget. 2017;8(59):99237-99244.
12. Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study. J Clin Oncol. 2016;34(23):2698-2704.
13. Booman M, Douwes J, Glas AM, et al. Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype charac- teristics. J Pathol. 2006;210(2):163-171.
14. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct patho- genic mechanisms and outcomes. Nat Med. 2018;24(5):679-690.
15. Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogen- esis of diffuse large B-cell lymphoma. N Engl J Med. 2018; 378(15):1396-1407.
haematologica | 2021; 106(5)
1471